Microcap Speculators
Here at microcap speculators we are in search of the very best speculative stocks. The reason why we are so interested in locating the top small cap stocks is because cheap illiquid stocks on Monday could be highly valued liquid stocks the next. Remember to never invest more into a speculative stock than you can afford to lose, and this is the key because should you be willing to gamble with your principal, it could pay off in a big way for you.
SUBSCRIBE TO OUR MONTHLY NEWSLETTER
Biotech employee faces 2 life terms for shooting co-worker - fox5sandiego.com
June 25, 2017
fox5sandiego.com |
Biotech employee faces 2 life terms for shooting co-worker
fox5sandiego.com SAN DIEGO -- A biotech employee accused of shooting a co-worker in the face at a warehouse in Carmel Mountain Ranch last Tuesday pleaded not guilty Monday to attempted premeditated murder and other charges. Superior Court Judge Lisa Rodriguez ... and more » |
Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers - TheStreet.com
June 25, 2017
TheStreet.com |
Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers
TheStreet.com Shares of Seattle Genetics Inc. (SGEN) fell 8.4% to $56.55 on Monday, June 26, as the company revealed Phase 3 study data for its Hodgkin lymphoma treatment. Though the data was positive and some on Wall Street expect the drug, adcetris, to be a $1.5 ... Biotech Rally Stumbles As These Small Caps Pull BackInvestor's Business Daily Bay State Biotech Report: Seattle Genetics and AlnylamBloomberg all 46 news articles » |
Biotech Rally Gets Second Wind As This Small Cap Nears Breaks Out - Investor's Business Daily
June 25, 2017
Investor's Business Daily |
Biotech Rally Gets Second Wind As This Small Cap Nears Breaks Out
Investor's Business Daily Exelixis (EXEL) stock flirted with a breakout Monday, helping the biotech sector regain its speed on a seven-day running spree as worries that President Donald Trump's administration could handcuff drug prices continued to subside. In afternoon trading ... and more » |
Could An FDA Delay Snag This Biotech's Pre-Term Birth Drug ... - Investor's Business Daily
June 25, 2017
Investor's Business Daily |
Could An FDA Delay Snag This Biotech's Pre-Term Birth Drug ...
Investor's Business Daily A delay at the FDA could expose Amag to generic competition for a drug meant to prevent preterm birth, analysts said Monday. and more » |
Biotech Boom!: Overview And Company-By-Company Review ... - Seeking Alpha
June 25, 2017
Investopedia |
Biotech Boom!: Overview And Company-By-Company Review ...
Seeking Alpha The biotech sector has been roaring back the past several weeks. Much of the reason relates to lessened anxiety over upcoming policies out of Washington, ... The Reason for the Big Rise in Biotech Stocks | InvestopediaInvestopedia iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB): Big ...ETF Daily News (blog) Source reports record flows into biotech ETF | ETF StrategyETF Strategy all 10 news articles » |
645% Growth May Push This Biotech Stock Into New Buy Zone - Investor's Business Daily
June 25, 2017
Investor's Business Daily |
645% Growth May Push This Biotech Stock Into New Buy Zone
Investor's Business Daily Boosted by explosive earnings growth in recent quarters and recent gains by fellow biotech stocks like Celgene (CELG), Exelixis (EXEL) and Regeneron (REGN), Innoviva (INVA) saw a sharp improvement to its Relative Strength (RS) Rating on Monday, ... |
How Biotech Patents Are Linked to US Food Productivity - MIT Technology Review
June 25, 2017
MIT Technology Review |
How Biotech Patents Are Linked to US Food Productivity
MIT Technology Review More recently, the biotech revolution has begun to have an impact. Genetically modified organisms now dominate many crops in the U.S. and are thought to be increasing productivity (although other parts of the world have been more cautious about the ... |
Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say. - Xconomy
June 25, 2017
|
Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.
Xconomy By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy, to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment. Newer ... |